These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 17896900

  • 1. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA, Kane MP, Busch RS.
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [Abstract] [Full Text] [Related]

  • 2. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN, Savage MW, Wiles PG.
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [Abstract] [Full Text] [Related]

  • 3. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR, Cha R, Brown MB, Jaber LA.
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [Abstract] [Full Text] [Related]

  • 4. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 5. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL.
    Diabetes Educ; 2008 May; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [Abstract] [Full Text] [Related]

  • 6. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A.
    Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
    [Abstract] [Full Text] [Related]

  • 7. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.
    Lam S, See S.
    Cardiol Rev; 2006 Aug; 14(4):205-11. PubMed ID: 16788334
    [Abstract] [Full Text] [Related]

  • 8. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [Abstract] [Full Text] [Related]

  • 9. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B.
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [Abstract] [Full Text] [Related]

  • 10. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM.
    Transplantation; 2007 Jan 15; 83(1):24-8. PubMed ID: 17220786
    [Abstract] [Full Text] [Related]

  • 11. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E, Halseth A.
    Horm Metab Res; 2006 Dec 15; 38(12):838-44. PubMed ID: 17163361
    [Abstract] [Full Text] [Related]

  • 12. Exenatide: a new option for the treatment of type 2 diabetes.
    Yoo BK, Triller DM, Yoo DJ.
    Ann Pharmacother; 2006 Oct 15; 40(10):1777-84. PubMed ID: 16985091
    [Abstract] [Full Text] [Related]

  • 13. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME.
    Diabet Med; 2006 Mar 15; 23(3):240-5. PubMed ID: 16492205
    [Abstract] [Full Text] [Related]

  • 14. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA, Cersosimo E.
    Am J Physiol Endocrinol Metab; 2008 May 15; 294(5):E846-52. PubMed ID: 18334612
    [Abstract] [Full Text] [Related]

  • 15. Incretin mimetics as a novel therapeutic option for hepatic steatosis.
    Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ.
    Liver Int; 2006 Oct 15; 26(8):1015-7. PubMed ID: 16953843
    [Abstract] [Full Text] [Related]

  • 16. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS.
    Horm Metab Res; 2005 Oct 15; 37(10):627-32. PubMed ID: 16278786
    [Abstract] [Full Text] [Related]

  • 17. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA, Govindan J, Baskar V, Kalupahana D, Singh BM.
    QJM; 2010 Sep 15; 103(9):687-94. PubMed ID: 20624837
    [Abstract] [Full Text] [Related]

  • 18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug 15; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 19. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov 15; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 20. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb 15; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.